RahulDoc

We have 35 doctors in Lok Sabha. Did any body raises there voice for dausa incidence. @IMAIndiaOrg @drrmittal

Sudden cardiac death: find out more Topic: From Stethoscope to Sequencer: Practical Cardiogenomics for the Modern Cardiologist Time: Mar 25, 2026 07:00 PM India Join Zoom Meeting zoom.us/j/96573555423?… Meeting ID: 965 7355 5423 Passcode: 819193 @RahulDoc2 @vinayak agarwal

@drshrinidhi2020 @vinayak Wonderful

1/ In NDMM, is Daratumumab the new norm - or are we letting PFS excitement outrun LMIC reality? Because yes: if the endpoint is PFS, Dara is winning. But if the endpoint is value, the debate is very much alive. #mmsm

@rajshekharucms @bdermanmd Interesting in majestic 3 would be to see those pt who have received dara what was the cumulative exposure of dara and what was the response.

@bdermanmd If Dara-R resistant, Cilta-Cel if CAR-eligible; single agent BCMA BsAb if CAR-ineligible or risk averse to CAR toxicities. Minimal to no role of ‘conventional’ therapies IMO

For a contemporary patient with myeloma that receives Dara-VRd induction, forgoes ASCT, and proceeds with maintenance, what would you recommend at relapse (assume Dara-R resistance)?

@bdermanmd @rajshekharucms How do one define dara resistance

@rajshekharucms Are you planning to do tec-Dara if Dara resistant? What if exposed but not resistant?

3/ Too early to call this durability, of course : but it is hard not to respect how powerfully GPRC5D-directed therapy can work in aggressive plasma cell disease.

2/ At relapse, marrow showed approximately 18–22% plasma cells, with serum free light chain ratio of 522 mg/L. After step-up dosing and the first full dose of talquetamab, repeat SFLC was 0.98 mg/L, with no CRS and no ICANS during admission.

1/ Seeing this kind of response is why newer myeloma immunotherapy space feels so transformative. In 77-year-old gentleman with relapsed plasma cell leukemia and prior teclistamab exposure, talquetamab produced a striking early biochemical response after the first full dose.

@beatalleukemia We have found more nras and kit mutation in 8:21 aml in India in comparison to American data base. Can we now compare aml 8:21 mutations among Indians living in India Indians living in America > 10 yr Americans means Americans @NitinJainMD

Had a fantastic time recording an in depth discussion on pre-malignant conditions in hematologic malignancies(CHIP/CCUS- myeloid malignancies ) with fearless leader Jen Woyach (MBL/CLL) & Elvira Umyrova (plasma cell disorders- multiple myeloma). ccme.osu.edu/continuing-med… @OSUHematology @OSUCCC_James

@bdermanmd @RahulBanerjeeMD We had one pt who developed all 5 ur after myeloma bmt and underwent a allogenic bmt after Blina based therapy.

A new manuscript provides a revealing window into lenalidomide-associated B-ALL. 57 patients had samples analyzed for molecular mutations. The high prevalence of TP53 mutations is no surprise What is novel is the high prevalence of IDH2 mutations (which is unique vs primary B-ALL).

ELN 2025 MRd!!!!! @rahuldoc2 @nikhilsjmc

Maroof's final message was shared by a common friend who is his batchmate from Mayo. #MaroofRaza “Don't cry for me, my dear ol' friends, All clocks stop their time, Last night they stopped for someone else, Today the call was mine. I've lived a life so full and free, With friends in Olive Green, We've played, we've battled, we've partied hard, The best of times we've seen. I followed a call my heart put forth, And took the scholar’s trail, Brought truth before the world at large, Never did my conscience fail. But then my friends ne'er do forget, That we are humans too, At times mistakes we may have made, Intent howe'er was true. Ask me today if regrets I’ll hold, For moving on today? In heaven I’ll miss my mates from here, And that's the price I'll pay. Don't cry for me my dear ol' friends, All clocks stop their time, Last night they stopped for someone else, Today the call was mine!!”

@NayabSainiBJP please help us to maintain the law and order @anilvijminister

@punitjn Wonderful

Presented allogeneic transplant data in 445 patients of acute lymphoblastic leukemia from India in Tandem 2026 at Salt Lake city, USA First-ever collaborative study from ISBMT 22 Indian centres Thanking all my coauthors from ISBMT !

@SwatiJaiHind What did ur aap do for the health care. Don’t criticise unnecessary

Private Hospital में इलाज करवाने की ज़रूरत पड़ जाए तो एक आम परिवार का घर-गहने गिरवी रखने तक की नौबत आ जाती है। अस्पताल में भर्ती होने से पहले ही ₹50,000-1,00,000 तक Advance रखवाया जाता है। अस्पतालों के कमरों का रेंट 5 स्टार के होटल से महँगे। बेड मिलते ही बिल में thermometer-sanitizer-masks-gloves सब बिल में जुड़ना शुरू हो जाते हैं। जो दवाएँ बाहर डिस्काउंट पर मिलती हैं वो अस्पताल में पूरे रेट पर मिलती है। लैब टेस्ट मान्य होती है तो सिर्फ़ अस्पताल की। आज संसद में ये ज़रूरी मुद्दा रखा।

Why so many global CEOs are Indian is the wrong question. The real question is what kind of system produces them. This isn’t about Indians being genetically smarter or IITs magically creating genius. It’s only about selection pressure. India is not a talent factory. India is a high-pressure talent filter. Most Indians are born into middle class or lower middle class families. There is no safety net, no fallback plan, no cushion. From the day you’re born there is an unspoken contract. Do well or the whole family stays stuck. Education isn’t optional. It’s survival, now add population. Five to ten lakh people fighting for a few thousand seats. Even after years of preparation, effort doesn’t guarantee success. You still have to win against insane odds. What comes out of this system is not creativity. It’s endurance. People who can sit for long hours, delay gratification for a decade, operate under pressure without breaking, and don’t feel entitled to comfort. That profile matters - Large global companies don’t reward raw brilliance at the top. They reward people who can survive complexity, politics, scale, and boredom for 20 to 30 years straight. That’s why Indian origin leaders show up disproportionately in operator roles. CEOs, presidents, heads of massive systems, not founders. They didn’t rise because they were the loudest or flashiest. They rose because they had already been trained by a brutal system that rewards consistency over brilliance. Compare that to a child born in a developed country. There is pressure, yes. But there is also a safety net. More options. Less existential fear. That environment is great for creativity and risk taking. It produces founders and innovators. India produces survivors who become operators. That’s the difference most people miss. And let’s be clear, this system is not something to romanticize. For every one person who makes it, millions burn out. Talent gets wasted. Mental health gets crushed. The system is inefficient and cruel. But it does one thing extremely well. It filters for people who can endure. That’s why Indians don’t dominate early stage innovation globally, but they dominate long-run leadership in established systems. So no, Indians aren’t exceptional because of IQ. They’re exceptional because they were never allowed to be comfortable. The uncomfortable question is not why this works. The real question is whether this is the only way we should be producing leaders. And whether the cost is worth it.

@DrGauravNarula @venkymd Even ur small part plays a big role in creating a brighter future for all of us in India. So proud of u and the entire group

Great work led by @venkymd Happy to have been a small part of it

@venkymd Wow

Use of Artificial Intelligence to predict relapse in Pediatric Acute Lymphoblastic Leukaemia. ICICLE pre trial cohort. AI performed better than clinicians in predicting relapse. #AI #Cancer #Oncology

@thisisJamesD @RahulBanerjeeMD @Bethfaiman Wonderful

Great article by @RahulBanerjeeMD @Bethfaiman et al reviewing the history and role of dexamethasone in plasma cell disorders. further solidifying the mantras #downwithdex and #DownWithDexExceptForCRS ascopubs.org/doi/10.1200/JC…

Fresh off the journal! Excited for the publication! 15 patients with Fanconi anaemia - MSD OS at 2 years - 93.7 % and EFS of 81.2%.